RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.14412/1995-4484-2011-1458
Abstract
Objective: to define the clinical value of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in early psori- atic arthritis (PA).
Subjects and methods. Fifty-six patients (32 females and 24 males) with early PA with a mean duration of 12±6.7 months were studied. The examinees' age ranged from 18 to 76 years (mean age 44±15.5 years). Mean psoriasis duration was 12.5±2.2 years. RF IgM was determined using a high-sensitive nephelometric method on a BN Pro-Spec analyzer (Siemens, Germany) and serum anti-CCP concentra- tions were measured by immunochemiluminescence on a COBAS e411 analyzer (Roche, Switzerland). Group 1 included 10 patients with anti-CCP and/or RF (a study group); Group 2 comprised 46 patients without anti-CCP and RF (a control group).
Results. There was anti-CCP in 7 (12.5%) of the patients with early PA, RF in 8 (14.3%), both of them in 5 (9%). The study group had a severer course of PA accompanied by polyarthritis, inflamed distal interphalangeal joints, axial arthritis, dactylitis, enthesitis, and, in some cases spondylitis and sacroiliitis. In groups 1 and 2, the number of tender joints was 17.6±4 and 10±1.5, respectively (p = 0.04); that of swollen ones, 12.6±1.5 and 7.0±1.1 (p = 0.02); DAS28 index, 5.9±1.7 and 4.5±1.5 (p = 0.02); ESR, 34.5±5.9 and 22±2.3 (p = 0.04), high-sensitive C reactive protein, 70±25.3 and 24.9±5.0 (p = 0.06); and Sharp ratio, 68.7±14.3 and 21.3±3.8 (p < 0.004).
Conclusion. In patients with early PA, anti-CCP and RF were encountered with an approximately equal frequency; at the same time, they were associated with polyarthritis, high disease activity, and an erosive process.
References
1. <div><p>Бадокин В.В. Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой и Н.В. Бунчука. М., 2001;82-90.</p><p>Barth W.F. Psoriatic arthritis sine psoriasis. In: Klippel J.N., Dieppe P., eds. Rheumatology. London: Mosby, 1994;341-3.</p><p>Агабабова Э.Р., Бадокин В.В., Эрдес Ш.Ф. и др. Разработка и апробация диагностических критериев псориатического артрита. Тер арх 1988;12:117-21.</p><p>Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr Rheum 2006;54:2665-73</p><p>Mc-onagle D., Conaghan P.G., Emery P. Psoriatic arthritis: a unified concept 20 years on. Arthr Rheum 1999;42:1080-6.</p><p>Swedler W., Wallman J., Froelich C. J. et al. Routine measurement of IgM, IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 1997;24:1037-44</p><p>Shmerling R.H., Delbanco T.L. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34.</p><p>Alenius G.M., Berglin E., Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006;65:398-400.</p><p>Gladman D.D., Shuckett R., Russell M.L. et al. Psoriatic arthritis (PsA) - an analysis of 220 patients. Q J Med 1987;62:127-41</p><p>Schellekens G.A., de Jong B.A., van den Hoogen F.H. et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis - specific autoantibodies. J Clin Invest 1998;101:273-81.</p><p>Meyer O., Labarre C., Dougados M. Anti-citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five years radiographic damage. Ann Rheum Dis 2003;62:120-6.</p><p>Avouac J., Gossec L., Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51</p><p>Vannini A., Cheung K., Fusconi M. et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease sampls: citrulline-dependent or not- Ann Rheum Dis 2007;66:511-6.</p><p>Matsui T., Shimada K., Ozawa N. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006;33:2390-7.</p><p>Abdel Fattah N.S., Hassan H.E., Galal Z.A., El Okda el S.E. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes 2009;19:44.</p><p>Cruyssen V.B., Hoffman I.E.A., Zmierczak H. et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.</p><p>Korendowych E., Owen P., Ravindran J. et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 2005;44:1056-60.</p><p>Inanc N., Dalkilic E., Kamali S. et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26:17-23.</p><p>Aletaha D., Neogi T., Silman A.J. et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthr Rheum 2010;62:2582-91</p><p>Helliwell P.S., Porter G., Taylor W.J. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis than rheumatoid arthritis. Ann Rheum Dis 2007;66:113-7.</p><p>Van Schaardenburg D., Lagaay A.M., Otten H.G. et al. The relation between classspecific serum rheumatoid factors and age in general population. Br J Rheumatol 1993;32:546-9</p><p>Ursum J., Bos W.H., van de Stadt R.J. et al. Different properties of ACPA and IgMRF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthr Res Ther 2009;11:75.</p><p>Bogliolo L., Alpini C., Caporali R. et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005;32:511-5</p><p>Vencovsky J., Machacek S., Sedova L. et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.</p></div><br />
Review
For citations:
Badokin V.V., Troshkina I.A., Alexandrova E.N. RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS. Rheumatology Science and Practice. 2011;49(5):32-37. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1458
Views:
31183
Email this article 